Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Manuel E. Rodríguez‐Fuentes"'
Obestatin signalling counteracts glucocorticoid‐induced skeletal muscle atrophy via NEDD4/KLF15 axis
Autor:
Tania Cid‐Díaz, Saúl Leal‐López, Fátima Fernández‐Barreiro, Jessica González‐Sánchez, Icía Santos‐Zas, Luis J. Andrade‐Bulos, Manuel E. Rodríguez‐Fuentes, Carlos S. Mosteiro, Vincent Mouly, Xesús Casabiell, Jose Luis Relova, Yolanda Pazos, Jesus P. Camiña
Publikováno v:
Journal of Cachexia, Sarcopenia and Muscle, Vol 12, Iss 2, Pp 493-505 (2021)
Abstract Background A therapeutic approach for the treatment of glucocorticoid‐induced skeletal muscle atrophy should be based on the knowledge of the molecular mechanisms determining the unbalance between anabolic and catabolic processes and how t
Externí odkaz:
https://doaj.org/article/6aba5e89c5064f319ade19594e974fcf
Obestatin signalling counteracts glucocorticoid‐induced skeletal muscle atrophy via NEDD4/KLF15 axis
Autor:
Vincent Mouly, José Luis Relova, Saul Leal-lopez, Jesus P. Camiña, Manuel E. Rodríguez‐Fuentes, Icía Santos-Zas, Luis J. Andrade‐Bulos, Jessica González-Sánchez, Yolanda Pazos, Carlos S. Mosteiro, Xesús Casabiell, Tania Cid-Díaz, Fátima Fernández‐Barreiro
Publikováno v:
Journal of Cachexia, Sarcopenia and Muscle, Vol 12, Iss 2, Pp 493-505 (2021)
Journal of Cachexia, Sarcopenia and Muscle
Journal of Cachexia, Sarcopenia and Muscle, In press, ⟨10.1002/jcsm.12677⟩
Journal of Cachexia, Sarcopenia and Muscle, Wiley Open Access/Springer Verlag, In press, ⟨10.1002/jcsm.12677⟩
Journal of Cachexia, Sarcopenia and Muscle, Wiley Open Access/Springer Verlag, 2021, 12 (2), pp.493-505. ⟨10.1002/jcsm.12677⟩
Journal of Cachexia, Sarcopenia and Muscle
Journal of Cachexia, Sarcopenia and Muscle, In press, ⟨10.1002/jcsm.12677⟩
Journal of Cachexia, Sarcopenia and Muscle, Wiley Open Access/Springer Verlag, In press, ⟨10.1002/jcsm.12677⟩
Journal of Cachexia, Sarcopenia and Muscle, Wiley Open Access/Springer Verlag, 2021, 12 (2), pp.493-505. ⟨10.1002/jcsm.12677⟩
International audience; Background: A therapeutic approach for the treatment of glucocorticoid‐induced skeletal muscle atrophy should be based on the knowledge of the molecular mechanisms determining the unbalance between anabolic and catabolic pro